While Big Pharma faces major products going off patent and drug regulators expect new products to have greater product efficacy, drug delivery formats that can enhance compliance, product performance or extend drug lifecycles are the new drivers.
Formulators are looking for technologies that provide controlled, sustained or delayed release and help to target delivery to where it is needed most. Blue sky technologies using miniaturised electronics, microneedles and smart pill are all helping to deliver sensitive drug payloads to previously hostile and inaccessible regions of the body. Many other companies are meeting the challenges of low bioavailability of oral solid drugs, the inconvenience of administering injections or improving dose accuracy and compliance. Even the conventional tablets and capsules market has evolved, achieving fast disintegrating and rapidly acting tablets or films.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
- Companies:
- MIT Massachusetts Institute of Technology
- Ablynx nv
- Lupin Pharma
- Georgia Institute of Technology
- Visiongain Ltd
- MonoSol Rx
- Alcon Group
- Centers for Disease Control and Prevention
- Novartis
- Tufts Center for the Study of Drug Development
- RNCOS
- Enteris BioPharma
- Alliqua
- MarketsandMarkets
- BioDelivery Sciences International Inc
- Rexahn Pharmaceuticals
- Applied Pharma Research
